Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives

J. Guillon, A. Cohen, RN. Das, C. Boudot, NM. Gueddouda, S. Moreau, L. Ronga, S. Savrimoutou, L. Basmaciyan, C. Tisnerat, S. Mestanier, S. Rubio, S. Amaziane, A. Dassonville-Klimpt, N. Azas, B. Courtioux, JL. Mergny, C. Mullié, P. Sonnet,

. 2018 ; 91 (5) : 974-995. [pub] 20180117

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035465

A series of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives was synthesized, and the compounds were screened in vitro against three protozoan parasites (Plasmodium falciparum, Leishmania donovani, and Trypanosoma brucei brucei). Biological results showed antiparasitic activity with IC50 values in the μm range. The in vitro cytotoxicity of these molecules was assessed by incubation with human HepG2 cells; for some derivatives, cytotoxicity was observed at significantly higher concentrations than antiparasitic activity. The 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline 1h was identified as the most potent antimalarial candidate with ratios of cytotoxic-to-antiparasitic activities of 107 and 39 against a chloroquine-sensitive and a chloroquine-resistant strain of P. falciparum, respectively. As the telomeres of the parasite P. falciparum are the likely target of this compound, we investigated stabilization of the Plasmodium telomeric G-quadruplexes by our phenanthroline derivatives through a FRET melting assay. The ligands 1f and 1m were noticed to be more specific for FPf8T with higher stabilization for FPf8T than for the human F21T sequence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035465
003      
CZ-PrNML
005      
20191014102251.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/cbdd.13164 $2 doi
035    __
$a (PubMed)29266861
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Guillon, Jean $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
245    10
$a Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives / $c J. Guillon, A. Cohen, RN. Das, C. Boudot, NM. Gueddouda, S. Moreau, L. Ronga, S. Savrimoutou, L. Basmaciyan, C. Tisnerat, S. Mestanier, S. Rubio, S. Amaziane, A. Dassonville-Klimpt, N. Azas, B. Courtioux, JL. Mergny, C. Mullié, P. Sonnet,
520    9_
$a A series of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives was synthesized, and the compounds were screened in vitro against three protozoan parasites (Plasmodium falciparum, Leishmania donovani, and Trypanosoma brucei brucei). Biological results showed antiparasitic activity with IC50 values in the μm range. The in vitro cytotoxicity of these molecules was assessed by incubation with human HepG2 cells; for some derivatives, cytotoxicity was observed at significantly higher concentrations than antiparasitic activity. The 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline 1h was identified as the most potent antimalarial candidate with ratios of cytotoxic-to-antiparasitic activities of 107 and 39 against a chloroquine-sensitive and a chloroquine-resistant strain of P. falciparum, respectively. As the telomeres of the parasite P. falciparum are the likely target of this compound, we investigated stabilization of the Plasmodium telomeric G-quadruplexes by our phenanthroline derivatives through a FRET melting assay. The ligands 1f and 1m were noticed to be more specific for FPf8T with higher stabilization for FPf8T than for the human F21T sequence.
650    _2
$a antiprotozoální látky $x chemická syntéza $x metabolismus $x farmakologie $7 D000981
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a G-kvadruplexy $7 D054856
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a Leishmania donovani $x účinky léků $x růst a vývoj $7 D007893
650    _2
$a ligandy $7 D008024
650    _2
$a fenantroliny $x chemie $x metabolismus $x farmakologie $7 D010618
650    _2
$a Plasmodium falciparum $x účinky léků $7 D010963
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a tranzitní teplota $7 D044366
650    _2
$a Trypanosoma brucei brucei $x účinky léků $7 D014346
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cohen, Anita $u Laboratory of Parasitology, UMR-MD3, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.
700    1_
$a Das, Rabindra Nath $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Boudot, Clotilde $u INSERM U1094, Tropical Neuroepidemiology, Limoges, France. Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, Limoges, France.
700    1_
$a Gueddouda, Nassima Meriem $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Moreau, Stéphane $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Ronga, Luisa $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Savrimoutou, Solène $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Basmaciyan, Louise $u Laboratory of Parasitology, UMR-MD3, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.
700    1_
$a Tisnerat, Camille $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Mestanier, Sacha $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Rubio, Sandra $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Amaziane, Sophia $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Dassonville-Klimpt, Alexandra $u Laboratoire de Glycochimie, des Antimicrobiens et des Agroressouces, UMR CNRS 7378, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France.
700    1_
$a Azas, Nadine $u Laboratory of Parasitology, UMR-MD3, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.
700    1_
$a Courtioux, Bertrand $u INSERM U1094, Tropical Neuroepidemiology, Limoges, France. Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, Limoges, France.
700    1_
$a Mergny, Jean-Louis $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France. Institute of Biophysics of the CAS, v.v.i., Brno, Czech Republic.
700    1_
$a Mullié, Catherine $u Laboratoire de Glycochimie, des Antimicrobiens et des Agroressouces, UMR CNRS 7378, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France.
700    1_
$a Sonnet, Pascal $u Laboratoire de Glycochimie, des Antimicrobiens et des Agroressouces, UMR CNRS 7378, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France.
773    0_
$w MED00173265 $t Chemical biology & drug design $x 1747-0285 $g Roč. 91, č. 5 (2018), s. 974-995
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29266861 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014102715 $b ABA008
999    __
$a ok $b bmc $g 1452125 $s 1074015
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 91 $c 5 $d 974-995 $e 20180117 $i 1747-0285 $m Chemical biology & drug design $n Chem Biol Drug Des $x MED00173265
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace